Welcome to our dedicated page for Orthopedia SEC filings (Ticker: KIDS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OrthoPediatrics Corp. (NASDAQ: KIDS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. OrthoPediatrics is a Delaware-incorporated orthopedic medical device company focused on pediatric orthopedics, and its filings offer detailed information on its financial condition, operations, and governance.
Investors can review current reports on Form 8-K, where OrthoPediatrics reports material events such as quarterly earnings releases, preliminary unaudited revenue updates, revisions to financial guidance, and presentations to investors and analysts. The company also uses Form 8-K to disclose board changes, including director retirements and new appointments, and to furnish press releases related to business developments like OPSB expansion.
In addition to 8-Ks, OrthoPediatrics files periodic reports such as Form 10-Q and Form 10-K, which contain unaudited and audited financial statements, segment information, and risk factor discussions referenced in its news releases. These documents provide context on revenue by category (trauma and deformity, scoliosis, sports medicine/other procedures, and specialty bracing), operating expenses, restructuring charges, intangible asset impairments, and non-GAAP measures such as adjusted EBITDA.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand changes in guidance, major cost items, and business drivers. Users can also track real-time updates as new filings are posted to EDGAR, including any future Forms 4 reporting insider transactions, proxy statements detailing director compensation, and other governance-related documents. This centralized view of KIDS filings allows investors, analysts, and researchers to examine OrthoPediatrics’ regulatory history, financial disclosures, and corporate actions in one place, supported by AI-generated explanations that clarify complex sections of the filings.
OrthoPediatrics Corp. reports continued clinical and financial progress in 2025, driven by product launches and geographic expansion. Full-year 2025 revenue reached $236.3 million, up 15% year-over-year, and the Company generated $10 million of free cash flow in Q4 2025 while reducing annual free cash flow usage by over 60% versus 2024. Management provided 2026 guidance of $262 million to $266 million in revenue (an 11–13% increase vs. 2025) and approximately $25 million of Adjusted EBITDA. The company highlights multiple product initiatives including the 3P pediatric plating platform, VerteGlide and eLLi Active Growing Implants, expanded OPSB specialty bracing, EU MDR/UK certifications and several acquisitions and clinic integrations that expand commercial reach.
OrthoPediatrics Corp. has called its 2026 annual meeting for June 4 to elect four directors, hold advisory votes on executive pay and auditor appointment, and approve an amendment to its 2024 Incentive Award Plan. As of April 6, 2026, 25,686,214 common shares were outstanding, each with one vote. The proxy details board structure, committee independence, social impact focus, and a pay program where 2025 bonuses for named executives paid out at 78.2% of target and long-term incentives were delivered in time-vested restricted stock.
OrthoPediatrics Corp. amended its existing term loan agreement to add a new delayed draw term loan facility of up to $20.0 million. Subject to conditions in the amendment, the company may draw this in minimum $10.0 million increments until June 30, 2027, allowing it to access capital as needed.
The facility carries interest at the SOFR Interest Rate with a 3.25% floor plus 6.50%, with an option for a 1.00% payment-in-kind component, and interest-only payments until the August 5, 2029 maturity. OrthoPediatrics will pay a 1.00% upfront fee and a 0.05% per annum delayed draw ticking fee, along with exit and prepayment fees consistent with the existing agreement.
ORTHOPEDIATRICS CORP executive Joseph W. Hauser reported a stock grant and related tax sale. He acquired 65,700 shares of Common Stock on March 15, 2026 as a grant at $0.00 per share, increasing his direct holdings to 203,363 shares.
On March 16, 2026, 8,596 shares were sold at $17.25 per share to satisfy tax withholding obligations upon vesting of restricted shares. After these transactions, he directly owned 194,767 shares of Common Stock, including restricted stock awards totaling 155,805 shares.
OrthoPediatrics Corp executive Fred Hite, the COO and CFO, reported both a stock grant and a related share sale. On March 15, 2026, he acquired 77,405 shares of Common Stock as a grant at $0.00 per share. On March 16, 2026, he sold 12,993 shares of Common Stock at $17.25 per share to satisfy tax withholding obligations upon vesting of restricted shares.
After these transactions, Hite directly owned 277,477 shares of OrthoPediatrics Common Stock, which the disclosure states includes restricted stock awards totaling 197,765 shares.
OrthoPediatrics Corp President and CEO David R. Bailey reported an open-market sale of 19,535 shares of common stock at $17.25 per share. According to the disclosure, these shares were sold to satisfy tax withholding obligations triggered when restricted stock vested, rather than as a discretionary portfolio move.
After this transaction, Bailey directly holds 298,020 shares of OrthoPediatrics common stock, which includes 187,891 shares of restricted stock awards. The sale represents only a portion of his overall equity position in the company.
OrthoPediatrics Corp President of Scoliosis Gregory A. Odle reported a stock compensation event combined with a tax-related share sale. He received a grant of 47,380 shares of common stock as a restricted stock award. The next day, 8,433 shares were sold specifically to satisfy tax withholding obligations upon vesting of restricted shares, according to the footnote. After these transactions, he directly holds 187,735 shares of common stock, which the disclosure states includes restricted stock awards totaling 121,054 shares.
OrthoPediatrics Corp General Counsel Daniel J. Gerritzen reported compensation-related stock activity. On March 15, he acquired 47,380 shares of common stock as a grant or award at $0.00 per share. On March 16, he sold 8,614 shares at $17.25 per share.
According to a footnote, the shares sold on March 16 were used to satisfy tax-withholding obligations tied to the vesting of restricted shares, rather than a discretionary sale. After these transactions, he directly holds 149,533 shares of common stock, which includes restricted stock awards totaling 121,054 shares.